| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Montesino Associates is a Sparta, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
Exalenz Bioscience is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.